Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1. Semaglutide (Rybelsus) - For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise

Semaglutide (Rybelsus) - For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise 1 Published 7 September 2020 Product update SMC2287 semaglutide 3mg, 7mg and 14mg tablets (Rybelsus®) Novo Nordisk 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following assessment under the abbreviated process semaglutide (Rybelsus®) is accepted for restricted use within NHSScotland. Indication under review: for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise ? As monotherapy when metformin is considered inappropriate due to intolerance or contraindications ? In combination with other

2020 Scottish Medicines Consortium

2. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison Full Text available with Trip Pro

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison - PubMed This site needs JavaScript to work properly. Please enable (...) options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Jul 6. doi: 10.1111/dom.14136. Online ahead of print. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison , , , , , , , , Affiliations Expand Affiliations 1 Translational and Clinical Research Institute, Newcastle University, Newcastle upon

2020 EvidenceUpdates

3. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study

Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA 1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 28;dc200736. doi: 10.2337/dc20-0736. Online ahead of print. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA 1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study , , , , , , , Affiliations Expand Affiliations 1 Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K. hood.thabit@mft.nhs.uk. 2 Division of Diabetes

2020 EvidenceUpdates

4. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial - PubMed This site needs JavaScript to work properly (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 21;dc192316. doi: 10.2337/dc19-2316. Online ahead of print. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial , , , , , , , , Affiliations Expand Affiliations 1 Dallas Diabetes Research Center at Medical City

2020 EvidenceUpdates

5. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) Full Text available with Trip Pro

Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Sep;43(9):2025-2033. doi: 10.2337/dc20-0408. Epub 2020 Jul 13. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) , , , , , , , , , , Affiliations Expand Affiliations 1 Steno Diabetes Center (...) of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) Alexander S Christensen et al. Diabetes Care . 2020 Sep . Free PMC article Show details Display options Display options Format Diabetes Care Actions . 2020 Sep;43(9):2025-2033. doi: 10.2337/dc20-0408. Epub 2020 Jul 13. Authors , , , , , , , , , , Affiliations 1 Steno Diabetes Center Copenhagen, Gentofte

2020 EvidenceUpdates

6. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2

Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) Metab Actions . 2020 Jul 3. doi: 10.1111/dom.14127. Online ahead of print. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 , , , , , , , Affiliations Expand Affiliations 1 Endocrine and Metabolic Consultants, Rockville, Maryland, USA. 2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 3 Diabetes Centers of America-Dallas

2020 EvidenceUpdates

7. Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis

Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) ? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Diabetes Care Actions . 2020 Aug;43(8):1967-1975. doi: 10.2337/dc19-1785. Time in Range for Multiple Technologies in Type 1 Diabetes

2020 EvidenceUpdates

8. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study

Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Aug 14;dc201104. doi: 10.2337/dc20-1104. Online ahead of print. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study , , , , , , Affiliations Expand Affiliations 1 (...) . PMID: 32801130 DOI: Item in Clipboard Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study Louise A Donnelly et al. Diabetes Care . 2020 . Show details Display options Display options Format Diabetes Care Actions . 2020 Aug 14;dc201104. doi: 10.2337/dc20-1104. Online ahead of print. Authors , , , , , , Affiliations 1 Population Health & Genomics, School of Medicine, University of Dundee, Dundee, U.K. 2 Institute of Biomedical & Clinical Science, University of Exeter Medical

2020 EvidenceUpdates

9. Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

% of adult-onset diabetes is late-onset type 1 (101). These patients have an increased risk of diabetic ketoacidosis, and there are no CV outcomes trial data for patients with type 1 diabetes. Patients taking insulin or an insulin secretagogue (i.e., a sulfonylurea or glinide) should be advised of the risk of hypoglycemic events when adding an SGLT2 inhibitor for CV bene?t, especially if HbA1c is already well-controlled at baseline. In these patients, discontinuing or weaning the sulfonylurea or glinide (...) Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes EXPERT CONSENSUS DECISION PATHWAY 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes A Report of the American College of Cardiology Solution Set Oversight Committee Endorsed by the American Diabetes Association Writing Committee Sandeep R. Das, MD, MPH, FACC, Co-Chair Brendan M. Everett, MD, MPH, FACC, Co-Chair Kim K. Birtcher, PHARMD, MS

2020 American College of Cardiology

10. Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial

Affiliations 1 Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. capresley@uabmc.edu. 2 Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 3 Cooper Green Mercy Health Services, Birmingham, AL, USA. PMID: 32700215 DOI: Item in Clipboard Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial (...) -based DSME with and without peer support led to improved glycemic control. Peer support linked to clinical care led to a larger reduction in diabetes distress, which has important implications for the overall wellbeing of adults with type 2 diabetes. Keywords: diabetes self-management education; mobile health; peer support. Similar articles Tang TS, Funnell MM, Sinco B, Spencer MS, Heisler M. Tang TS, et al. Ann Fam Med. 2015 Aug;13 Suppl 1(Suppl 1):S27-35. doi: 10.1370/afm.1819. Ann Fam Med. 2015

2020 EvidenceUpdates

11. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Incretin in Diabetes (REWIND) trial. Methods: REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries. We included men and women (aged ≥50 years) with either established or newly diagnosed type 2 diabetes and additional cardiovascular risk factors, glycated haemoglobin of up to 9·5% (80 mmol/mol) on a maximum of two oral glucose-lowering drugs with or without basal insulin, and a body-mass index of at least 23 kg/m 2 . Participants were randomly assigned (1:1 (...) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get

2020 EvidenceUpdates

12. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D , , , , , Affiliations Expand Affiliations 1 Texas Diabetes & Endocrinology, Austin, TX. 2 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN. 3 National Research Institute, Los Angeles, CA. 4 Jinnouchi Hospital, Kumamoto, Japan. PMID: 32616612 DOI: Item in Clipboard Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 (...) Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features

2020 EvidenceUpdates

13. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial Full Text available with Trip Pro

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial - PubMed This site needs JavaScript (...) ) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial , , , , , , , , , Affiliations Expand Affiliations 1 Children's Hospital AUF DER BULT, Hannover Medical School, Hannover, Germany danne@hka.de. 2 Department of Pediatrics, Yale University School of Medicine, New Haven, CT. 3 Department of Pediatrics, Bashkir State Medical University, Ufa, Russian Federation. 4 CPCLIN Clinical Research Center, São Paulo, Brazil. 5 Department

2020 EvidenceUpdates

14. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review Full Text available with Trip Pro

Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Psychological treatments may offer limited clinical benefit in improving HbA1c for adults with type 2 diabetes, but there was no benefit in adults or children with type 1 diabetes. {{author}} {{($index , , , , , , & . Kirsty Winkley 1, * , Rebecca Upsher 2 , Daniel Stahl 3 , Daniel Pollard 4 , Architaa Kasera 2 , Alan Brennan 4 , Simon Heller 5 , Khalida Ismail 2 1 Florence Nightingale Faculty of Nursing

2020 NIHR HTA programme

15. Type 1 and Type 2 diabetes and COVID-19 related mortality in England

Type 1 and Type 2 diabetes and COVID-19 related mortality in England NHS England » Type 1 and Type 2 diabetes and COVID-19 related mortality in England Cookies on the NHS England and NHS Improvement website We’ve put some small files called cookies on your device to make our site work. We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site. Let us know if this is OK. We’ll use (...) a cookie to save your choice. You can before you choose. Change my preferences I'm OK with analytics cookies Search Search Menu . If you are a member of the public looking for health advice, go to the . And if you are looking for the latest travel information, and advice about the government response to the outbreak, go to the . Type 1 and Type 2 diabetes and COVID-19 related mortality in England Document first published: 20 May 2020 Page updated: 19 May 2020 Topic: , Publication type: Document PDF 497

2020 NHS England

16. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial

and microalbuminuria were recruited from a single center from April 1, 2013, through March 31, 2016, with a 5-year follow-up, including prespecified intermediate analysis at 24-month follow-up. Intervention: A total of 100 patients with type 2 diabetes, obesity (body mass indexes of 30 to 35 [calculated as weight in kilograms divided by height in meters squared]), and stage G1 to G3 and A2 to A3 CKD (urinary albumin-creatinine ratio [uACR] >30 mg/g and estimated glomerular filtration rate >30 mL/min) were (...) Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other

2020 EvidenceUpdates

17. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial Full Text available with Trip Pro

of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Eur Heart J Actions . 2020 Jun 24;ehaa419. doi: 10.1093/eurheartj/ehaa419. Online ahead of print. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial , , , , , Affiliations Expand Affiliations 1 Division of Molecular & Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School (...) A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes

2020 EvidenceUpdates

18. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial

Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Aug;43(8):1822-1828. doi: 10.2337/dc20-0124. Epub 2020 May 29. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators iDCL Trial Research Group

2020 EvidenceUpdates

19. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. (Abstract)

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease.In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter (...) of serious adverse events was similar in the two groups.We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov number, NCT02017171.).Copyright © 2020 Massachusetts Medical Society.

2020 NEJM

20. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes.To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes.Randomized clinical trial conducted at 22 (...) ); and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate.Of the 203 participants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mean HbA1c, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6. Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes per day) at baseline and 2.7% (39 minutes per day) during

2020 JAMA